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ARTICLE OPEN
Tissue-specific transcriptional imprinting and heterogeneity in
human innate lymphoid cells revealed by full-length single-cell
RNA-sequencing
Luca Mazzurana1, Paulo Czarnewski 2, Viktor Jonsson3, Leif Wigge3, Markus Ringnér 4, Teresa C. Williams1, Avinash Ravindran5,
Åsa K. Björklund 6, Jesper Säfholm7, Gunnar Nilsson5, Sven-Erik Dahlén7, Ann-Charlotte Orre8, Mamdoh Al-Ameri8,9, Charlotte Höög10,
Charlotte Hedin 10,11, Sylwester Szczegielniak11, Sven Almer 10,11 and Jenny Mjösberg1
The impact of the microenvironment on innate lymphoid cell (ILC)-mediated immunity in humans remains largely unknown. Here
we used full-length Smart-seq2 single-cell RNA-sequencing to unravel tissue-specific transcriptional profiles and heterogeneity of
CD127+ ILCs across four human tissues. Correlation analysis identified gene modules characterizing the migratory properties of
tonsil and blood ILCs, and signatures of tissue-residency, activation and modified metabolism in colon and lung ILCs. Trajectory
analysis revealed potential differentiation pathways from circulating and tissue-resident naïve ILCs to a spectrum of mature ILC
subsets. In the lung we identified both CRTH2+ and CRTH2− ILC2 with lung-specific signatures, which could be recapitulated by
alarmin-exposure of circulating ILC2. Finally, we describe unique TCR-V(D)J-rearrangement patterns of blood ILC1-like cells,
revealing a subset of potentially immature ILCs with TCR-δ rearrangement. Our study provides a useful resource for in-depth
understanding of ILC-mediated immunity in humans, with implications for disease.
Cell Research (2021) 0:1–15; https://doi.org/10.1038/s41422-020-00445-x
INTRODUCTION
Innate lymphoid cells (ILCs) are a recent addition to innate
immunity, playing an important role in clearing intra- and
extracellular pathogens, regulating adaptive immunity, tissue repair
and contributing to inflammation.1 Their defining feature is a lack of
rearranged antigen-specific receptors, which distinguishes them
from T cells. However, in other ways these cells closely mirror the
function of their adaptive counterparts, being an essential source of
cytokines related to type 1, 2 and 17 immune responses.1 Currently,
ILCs are classified into five subsets: ILC1, ILC2, ILC3, Natural killer (NK)
cells and lymphoid tissue inducer (LTi) cells. ILC1 produce interferon-
gamma (IFN-γ) and are dependent on the T-box transcription factor
(TF) TBX21 (Tbet) for their development and function. NK cells share
these features with ILC1, but they additionally express the TF
Eomesodermin homolog (Eomes) and have the ability to produce
cytolytic and cytotoxic molecules.1 ILC2s produce IL-13 and IL-5, and
are dependent on GATA-3.1 Both LTi cells and ILC3 can produce IL-
17 and IL-22 cytokines, and are dependent on the nuclear receptor
ROR-γt.1 Transcriptional analysis of ILCs obtained from different
human and mouse tissues has revealed tissue-specific transcriptional
imprinting.2–4 However, these studies relied on biased definition of
ILC populations sorted in bulk, masking potential heterogeneity and
misdefinition of ILC populations across tissues. Recent developments
in single-cell technologies on the transcriptional and protein level
have rapidly advanced our understanding of the heterogeneity of
the human immune system.5 While protein analyses still suffer from
limitations, e.g., in terms of cell number requirements, single-cell
RNA-sequencing (scRNA-seq) enables an unbiased, transcriptome-
wide analysis of even small numbers of cells. So far, scRNA-seq of
specific subsets of ILCs (NK cells,6 ILC27) or in specific tissues8,9 has
been performed in mice. Similarly, in humans, scRNA-seq has been
restricted to one subset (NK cells6) or one tissue (ileum10,11 and
tonsil12) at a time, yielding limited understanding of tissue-specific
imprinting of ILCs.
In this study, we analyzed human ILCs through full-length
scRNA-seq, combining data from four different tissues: blood,
tonsil, lung and colon. Comparison between tissues revealed
tissue-specific transcriptional imprinting, and gave us the possi-
bility to, for the first time in humans, compare scRNA-seq profiles
of ILCs in the circulation, secondary lymphoid organs
(SLOs) and mucosal tissues. Our data, which is provided as a
publically available resource, reveal previously unknown functions
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of human ILCs and extend our current understanding of human
ILCs biology.
RESULTS
ScRNA-seq reveals subset- and tissue-specific transcriptional
imprinting
Transcriptional profiling of ILCs across tissues on the bulk2,3 or
single-cell level6,7,9 in humans and mice have revealed unique
features of ILCs that are dependent on the tissue microenviron-
ment. Here we performed flow cytometric sorting of human
CD127+ ILCs from three tissues representing two distinct immune
cell compartments: circulation (blood), and mucosal tissue (lung
and colon) (3–4 donors/tissue) (Fig. 1a; Supplementary Informa-
tion Fig. S1). As reference populations we included selected NK
populations along the spectrum of previously described tissue NK
cell phenotypes. Predominantly recirculating CD56dimCD16+ NK
cells were sorted from the lung13 and predominantly tissue-
resident NK cells were sorted as bulk CD56+ from the gut14 or as
CD56brightNKG2A+ NK cells from the tonsil.12 Cells were next
processed for full-length Smart-seq2 scRNA-seq to unravel in-
depth tissue-specific transcriptional profiles and heterogeneity.
Our own previously published Smart-seq2 scRNA-seq dataset of
CD127+ ILC and NK cells from tonsils,12 representing a SLO, was
included in the analysis. All datasets were combined and analyzed
together in order to identify common and distinct patterns across
tissues and cell types (Fig. 1a). Low quality cells and a minor
fraction of contaminating cells lacking expression of PTPRC
(encoding CD45) and expressing transcripts of antigen-
presenting cells (e.g., high expression of HLA-DQA1, HLA-DRA
and HLA-DPA1 at levels exceeding ILC) were identified and
removed (Supplementary Information, Fig. S2), resulting in the
analysis of a total of 2956 cells distributed across four tissues
(Fig. 1b; Supplementary Information, Fig. S2).
Cell embedding using uniform manifold approximation and
projection (UMAP)15 revealed that all ILC subsets as well as NK
cells separated according to tissue of origin and FACS cell subset
annotation as inferred from index sorting (Fig. 1b, c). Unbiased
graph-based clustering subdivided cells into 20 clusters that
segregated cells both by tissue of origin and FACS phenotype
(Fig. 1d). On average, we observed 90% agreement between
protein FACS phenotype and the clusters identified in scRNA-seq
(Supplementary Information, Fig. S3a). We next used previously
described human ILC subset-specific TFs and cell surface
markers12 to annotate the clusters (Fig. 1e, f). Clusters 5 (lung),
15 (tonsil) and 19 (colon), expressing NKG7, EOMES and GZMA/B
but lacking IL7R were annotated as NK cells. Clusters 8 (blood), 13
(tonsil), 18 (lung) expressed IKZF3 (encoding the TF and zinc finger
protein Aiolos) but lacked EOMES, and KIR2DL1/3, and were
conditionally annotated as ILC1. Cluster 17 consisted of both tonsil
and blood CD127+ ILCs, which expressed low levels of EOMES,
conditionally annotating them as EOMES+ ILC1. Clusters 6 (blood),
11 (tonsil) and 12 (lung) were annotated as ILC2 on the basis of
uniquely high GATA3, MAF, PTGDR2 and HPGDS expression (Fig. 1e,
f). As predicted by the low frequency of human colon ILC1 and
ILC2 in non-inflamed colon tissue,16 colon cells with a FACS
phenotype of ILC1 and ILC2 (total 10 cells) did not generate
distinct clusters. ILC3s were annotated on the basis of RORC, IL23R,
IL1R1 and KIT expression (cluster 4 and 9 in tonsil, 2 and 10 in lung
and 0, 1, 3 and 14 in colon) (Fig. 1e, f). We also observed IL7R and
KIT-expressing ILCs in the blood (cluster 7) as well as in colon and
lung (cluster 16), which lacked transcripts of all master TFs (Fig. 1e,
f), reminiscent of the previously described ILC progenitors in blood
and tissues.12,17 These cells were annotated as naïve ILCs (nILCs),
consistent with the nomenclature for naïve T cells.18 Importantly,
cells from all donors of each tissue were present in all annotated
cell types (Fig. 1g) and clusters (Supplementary Information,
Fig. S3b, c) for each tissue.
Migration- and tissue-resident transcriptional profiles of ILCs
To identify conserved gene expression patterns that are shared
across tissues and cell types, we used a two-step approach rather
than simple differential expression (DE), which reveals differences
but not similarities between cell types and tissues. DE gene lists
for each annotated cell type and the overlaps between cell types
and tissues are provided in Supplementary Information, Data S1.
For the two-step approach, we selected the top DE genes in any of
the 20 clusters (4410 genes) and subsequently performed
weighted gene co-expression network analysis (WGCNA) for
identification of 100 gene modules (see Materials and Methods
for details) (Fig. 2a, b; Supplementary Information, Data S1). A high
number of modules were chosen in order to avoid forcing genes
with different expression patterns into the same group. Modules
with highly correlated expression are indicated with a connecting
line in the graph (Fig. 2c). Next, modules were scored individually
for their contribution to discriminating tissues, cell types and/or
cell clusters (Fig. 2c; Supplementary Information, Fig. S3d).
Notably, gene modules did not contribute equally to explaining
metadata and thus only modules that contributed to at least one
cell type or tissue were selected for further in-depth analysis
herein (Fig. 2c).
The analysis of four different tissues that represent unique
immune niches (circulation, lymphoid- and mucosal tissue) in
combination with the unbiased gene module analysis allowed us
to identify conserved patterns across tissues and cell types
(Fig. 2d). We identified two gene modules (41 and 11) containing
transcripts highly correlated to the expression of the prototypical
T cell migratory molecules S1PR1 and SELL (encoding L-selectin;
CD62L), respectively (Fig. 2d). Genes in these two modules were
highly expressed in tonsil and blood ILCs, including nILCs. The
modules included the glycolysis-associated transcript LDHB, the
adhesion molecule transcript ICAM3, as well as transcripts for
several S100 proteins (S100A4, S100A6 and S100A11) (Fig. 2d),
shown to be involved in migration.19 Module 23 was also over-
represented in blood and tonsil and contained transcripts for
several integrins including ITGB2 (CD18) ITGAL (CD11a) and ITGAM
(CD11b) (Fig. 2d). CD18 complexes with CD11 molecules to form
the adhesion molecules lymphocyte function-associated antigen-1
(LFA-1), which together with CD62L are involved in endothelial
tethering and firm adhesion. In sharp contrast to the migratory
phenotype of blood and tonsil ILCs, we also identified gene
modules indicative of tissue residency of lung and colon ILCs,
including tissue nILCs and to some extent also of tonsil ILCs.
Module 54 revealed a set of genes highly correlated to the
expression of the prototypical tissue-residency-associated marker
CD69 (Fig. 2d). We confirmed the diametrically opposed migratory
vs tissue-residency profiles of blood as compared to colon ILCs by
demonstrating the absence of CD69 and high expression of CD18
and CD62L on blood ILCs and low expression of CD18 and CD62L
and high expression of CD69 on colon ILCs (Fig. 2e). Tonsil showed
a mixed phenotype, regardless of mechanic or enzymatic isolation
of the cells (Fig. 2f), with low expression of CD62L, intermediate
expression of CD18 and some cells expressing CD69, aligning with
the presence of both tissue resident and migratory ILCs in
secondary lymphoid tissues in mice.20 CD69+ tonsil ILCs expressed
lower levels of CD18 as compared to CD69– tonsil ILCs (Fig. 2g).
Similarly, expression of NKp44 was associated with reduced
expression of CD18 (Fig. 2g). These data not only validate the
transcriptional findings but also show that in contrast to colon,
tonsil CD69+ express the endothelial adhesion integrin CD18, as
described for intravascular liver-resident T cells.21
Showing a similar expression pattern, we identified module 7 as
containing genes previously reported in human tissue resident
T cells22 involved in Fos/Jun signaling (FOS, FOSB, FOSL2 and
JUNB), NFκB signaling (NFKBIZ, NFKBID, NFKBIA, NFKB1 and NFKB2),
adhesion (ICAM1) and CXCR4 (Fig. 2d). In this module were also
transcripts of effector molecules such as CXCL2, CXCL1 and AREG,
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the latter previously reported as an ILC2 effector molecule.23 The
expression of MAFF, KLF4, NFIL3 and NR4A1 in tissue ILCs suggests
that these TFs are involved in transcriptional programs of
activation and/or tissue-residency in colon, lung and tonsil ILCs.
Module 6, which was particularly expressed in mature but not
nILCs in colon and lung, contained transcripts of additional
nuclear receptor subfamily four group members, NR4A2 and
NR4A3, as well as the hyaluronic acid receptor CD44, previously
shown to be expressed by tissue-resident T and NK cells13,22
(Fig. 2d). This module also contained transcripts involved in lipid
metabolism (ELOVL5 and PTGS2). The expression of STAT3,
NOTCH2, DLL1, RORA and RARA suggests a potential role for
STAT3-, Notch-, retinoic acid- and cholesterol-derivative (e.g.,
oxysterol) signaling in controlling activation and/or tissue-
residency of colon and lung ILCs (Fig. 2d). Colon and lung ILC3,
but to a lesser extent tonsil ILC3 expressed transcripts encoding
the receptors for IL-4 (IL4R), IFN-γ (IFNGR2) and CXCL16 (CXCR6),
raising the possibility that these factors are involved in the tissue-
specific regulation of colon and lung ILC3. Furthermore, we
identified module 34, containing lung-restricted transcripts
Fig. 1 ScRNA-seq reveals subset and tissue-specific transcriptional imprinting. a Summary of the experimental workflow. Arrows in data
integration and analysis section visualize the concept of immune cell migration between the tissues analyzed. Tonsil data was obtained from12
using the same scRNA-seq platform. b UMAP visualization of all cells (n= 2956) color-coded on the basis of tissue origin. c UMAP visualization
of all cells, color-coded on the basis of cell surface phenotype inferred from indexed FACS sorting. d UMAP showing unbiased graph-based
clustering analysis of all cells. e UMAP of annotated clusters. C_, colon; L_, lung; B_, blood; T_, tonsil; nILC, naïve ILC. f Dotplot displaying
expression of selected and previously described human ILC subset-specific TFs and cell surface markers used to annotate clusters in e.
g Barplot showing the representation of each donor in each annotated cluster in e. Data are from ten independent experiments with one
tissue donor each (blood= 3, lung= 4 and colon= 3) integrated with data from.12
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indicative of tissue-residency22 including LMNA and the TFs KLF10
and BCL3 (Fig. 2d), the latter involved in NFκB signaling.
In summary, we identified three gene modules allowing for the
characterization of the lymphoid- and peripheral tissue homing
properties of tonsil and blood ILCs, including blood nILCs. Four
additional modules contained transcripts for known and potential
activation and/or tissue-residency associated proteins that
showed tissue-restricted expression across colon, lung and tonsils.
Most of these genes were highly expressed by colon and lung
ILCs, including tissue nILCs, but to some extent also by tonsil ILCs.
Importantly, these genes were not expressed by blood ILCs,
including blood nILCs. Furthermore, lung NKdim cells, which have
been reported as circulating13 also showed low expression of
transcripts known to be associated with tissue-residency.
Gene modules reveal subset- and tissue-specific profiles of ILC3
Module 6 specified shared characteristics of putative tissue-
resident ILCs in lung and colon (Fig. 2d). Notably, some of the
Article
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genes in this module were particularly confined to ILC3 in these
two tissues (Fig. 3a, b). These included transcripts encoding HLA-
DR, -DP and -DQ (Fig. 3b), which we previously described in the
tonsil.12 Additional transcripts in this module included IRF4 and
BCL2A1, indicating a potential role for these transcripts in
establishing tissue-unique features of human colon and lung
ILC3. Also the transcript for the effector cytokine GM-CSF, CSF2
and BHLHE40, the latter a metabolism-related gene reported to
regulate GM-CSF production in mouse ILC3,24 as well as CXCL8 and
VEGFA were expressed in lung and colon ILC3 (Fig. 3b), further
indicating colon and lung-associated transcriptional imprinting of
ILC3 as compared to tonsil ILC3. However, colon and tonsil ILC3
also shared striking similarities with respect to high expression of
the prototypical ILC3 transcripts NCR2, IL23R, NRP1, IKZF2,
TNFSF13B, CCL20, JAML, PECAM1, TOX, RBPJ and CD300LF as well
as the previously described Th17 cell transcript IL4I1 (Fig. 3b). Of
interest, colon ILC3 expressed both LTA4H, encoding the
leukotriene B4 (LTB4) forming enzyme LTA4-hydrolase, and the
transcript coding for the receptor for LTB4, LTB4R, indicating a role
for LTB4 in colon-specific regulation of ILC3 function. Further
strengthening this hypothesis, a subset of colonic ILC3 expressed
the LTB4R surface protein (Fig. 3c). A comparison of DE gene
expression between lung, colon and tonsil ILC3 is provided as part
of Supplementary Information, Data S1.
Module 3 contained ILC3-related genes that were expressed by
ILC3 in all tissues but at particularly high level and frequency in
colon ILC3 (Fig. 3b). These included surface molecule transcripts
KIT, IL1R1, ICOS, CCR6, TNFSF11 (encoding RANK ligand), TNFSF4
(encoding OX40 ligand), the ITIM-containing CD96 and the
tetraspanin CD81. We also identified transcripts for the TFs RORC
and AHR, the signaling molecule PTPN22 and the cytokine LIF as
preferentially highly expressed by colon ILC3 (Fig. 3b).
Finally, we evaluated the transcriptional profile of the clusters of
cells that were termed nILCs in blood and tissues (colon and lung)
on the basis of lack of markers associated with mature ILCs
(Fig. 1f). From the evaluation of ILC3 (Fig. 3a, b) it became obvious
that these cells show few transcriptional parallels to ILC3 despite
their phenotypical similarities as assessed by flow cytometry.
Expression of genes associated with migration and tissue-
residency revealed a clear migratory behavior of blood nILCs
whereas tissue nILCs showed features of tissue residency (Fig. 2d).
A list of DE genes unique for blood and tissue nILCs is provided as
part of Supplementary Information, Data S1. This list includes TFs
of potential importance for the differentiation of nILCs in blood
(e.g., TCF7) and lung/colon (e.g., XBP1 and BATF) (Supplementary
Information, Data S1).
In summary, we unveil the transcriptional features of nILCs in
blood and tissues and reveal tissue-specific differences among
ILC3 and potential novel functions of these cells by description of
transcripts previously not known to be expressed by human ILC3.
A spectrum of mucosal ILC3 transcriptional states branching in
trajectory analysis
Next we performed trajectory analysis via Slingshot25 to under-
stand the potential relationships between the putative nILCs
identified in blood and tissues, and the more mature ILC subsets
and the potential spectrum of activation states of ILC3 in colon
and lung. Overlaying these trajectories with the clusters identified
in Fig. 1d (Fig. 3d) not only illustrated the heterogeneity among
ILC3 in colon, lung and tonsil but also inferred the potential
transcriptional relationships between these transcriptionally dis-
tinct ILC3 subclusters (Fig. 3e, f; Supplementary Information,
Fig. S4a, b). ILC3s were particularly heterogeneous in the colon
where four subclusters could be identified through Louvain
clustering (colon ILC3a–d, lung ILC3a–b, tonsil ILC3a–b) (Figs. 1d,
3e, f; Supplementary Information, Fig. S4a). Some of these clusters
were dominated by, but not unique to, individual donors as cells
from all donors of each tissue were present in all clusters
(Supplementary Information, Fig. S3b, c) for each tissue. Of
importance, the TF IKZF2 and the master ILC3 TFs RORC and AHR
were expressed across all ILC3 subclusters in all tissues, assigning
them to the ILC3 lineage (Supplementary Information, Fig. S4c).
Analysis comparing clusters within each tissue and focusing on
the top 20 DE genes (Supplementary Information, Data S2),
revealed that colon ILC3a (cluster 1) contained cells with an
activated and potentially tissue-resident phenotype, expressing
transcripts for multiple effector molecules involved in chemotaxis
and recruitment of immune cells including CSF2, XCL1, XCL2,
CXCL8, S100A4 and S100A6 (Fig. 3e). EGR1, EGR2 and KLF6,
encoding TFs involved in immune cell activation,26,27 and BCL2A1,
coding for an anti-apoptotic protein, were also enriched in this
cluster of cells. The prototypical ILC3 cytokine IL22 and the
activation marker NCR2 were expressed in colon ILC3a, as well as
in colon ILC3b (cluster 0) (Fig. 3g, h); the latter also showed an
activated phenotype with expression of genes involved in
glutamate response and lipid metabolism, respectively (GRM7
and LTA4H). Colon ILC3a was most similar to lung ILC3a (cluster 2)
in terms of XCL1, XCL2, S100A4, EGR2 and IFITM2, but also shared
similarities with lung ILC3b (cluster 10) in terms of CXCL8, CD83
and PTGS2 (encoding COX2) (Fig. 3e, f). ILC3s in the lung also
branched into two subclusters, indicating distinct transcriptional
trajectories which both contained features of activation and tissue
residency (Fig. 3f). The activated phenotype of colon ILC3a stood
in sharp contrast to colon ILC3d (cluster 14), which was most
similar to lung ILC3b (Supplementary Information, Data S2). Colon
ILC3d additionally expressed SELL (encoding CD62L), also
expressed by tonsil ILC3b (cluster 4) (Supplementary Information,
Fig. S4a),12 S1PR1, ITGAX and GPR183 (Fig. 3e), indicative of a
migratory behavior reminiscent of LTi-like cells contributing to
colonic lymphoid structure formation in a GPR183-dependent
manner in mice.28 Importantly, colon ILC3d formed a separate
branch in trajectory analysis and were transcriptionally distinct
from the tissue nILCs (Fig. 3e).
In summary, ILC3s show a high degree of transcriptional
heterogeneity, in particular in the colon where we identified a
spectrum of ILC3 states with variable activation status which
separated into different branches in trajectory analysis, ranging
from cells with a migratory phenotype, to ILC3-expressing effector
molecules important for metabolic adaptations, tissue repair and
immune cell recruitment.
Fig. 2 Migration and tissue-resident transcriptional profile of ILCs. a Summary of analysis approach used to identify gene modules and perform
trajectory analysis. b UMAP visualization of all cells, color-coded on the basis of tissue origin. c Circular dendrogram illustrating the number and
composition of each module and the contribution of each module to discriminating cell clusters, tissues and cell types (as inferred from FACS).
Modules with highly correlated expressions are indicated with a 5-NN graph (connecting lines represent KNN; k nearest neighbor). Modules
described in text are marked with an asterisk. d Modules highly correlated with tissues and/or cell types/clusters containing genes involved in
migration or tissue residency. The figure shows a selection of genes per module, and their levels of expression within annotated clusters (Fig. 1e).
Data in a–d is from ten independent experiments with one tissue donor each (blood= 3, lung= 4 and colon= 3) integrated with data from.12
e Co-expression of CD69 and CD18/CD62L (top row) and NKp44 and CD18/CD62L (bottom row) on total ILCs from blood, tonsil and colon
biopsies. f Histogram showing the expression of CD18, CD62L and CD69 on mechanically or enzymatically isolated total tonsil ILCs. FMO,
fluorescence minus one. g Bar plot quantification of the results shown in e. MFI, mean fluorescence intensity. Data in e–g are from six independent
experiments with at least one tissue donor each (blood= 6, tonsil= 8 and colon= 6).
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Gene modules reveal subset- and tissue-specific profiles of ILC2
Our gene module approach identified a set of genes that were
specifically expressed in ILC2 across the three tissues (Fig. 4a, b),
making up an ILC2 core transcriptome. These genes included, as
expected, GATA3 and MAF, as well as HPGD, HPGDS and MBOAT2,
the latter three encoding proteins involved in lipid metabolism.
Furthermore, ILC2 in all tissues expressed transcripts for the IL-9
receptor (IL9R). Other genes in the module were particularly
expressed in blood ILC2 or blood and tonsil ILC2, including
transcripts for receptors involved in cell trafficking and migration
such as the prototypical ILC2 marker CRTH2 (PTGDR2), S1PR2 and
CCR2, the latter shown to be involved in the regulation of S1P
Article
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receptors.29 The TNF family-related transcripts TNFSF10 (encoding
TRAIL) and TNFRSF19 (encoding TROY) were also highly expressed
by blood and tonsil ILC2, as well as CD200R1, possibly acting as an
inhibitory receptor for human blood and tonsil ILC2. Another ILC2-
related module was less restricted to ILC2 but still contained
transcripts relevant for ILC2 biology, particularly for the potential
negative regulation of these cells; IL10RA,30 KLRG1,31 PTGER2,32
ANXA133 as well as LGALS1, encodes the immunosuppressive
molecule galectin-1.
Finally, we identified a module of genes (number 65) specifically
expressed in lung, but not tonsil or blood ILC2 (Fig. 4b). Expression
of the main effector molecule IL13 indicated that lung ILC2 are
highly activated. Indeed, lung ILC2 showed high expression of
IL1RL1 and IL17RB, encoding the receptors for the ILC2-activating
alarmins IL-33 and IL-25, respectively. Additional transcripts for
potential activating receptors included the SLAM-family receptor
SLAMF1, TNFRSF9, the fatty acid receptors FFAR3 and PPARG, the
latter shown to activate ILC2 in mice.34
The fact that blood ILC2 showed a phenotype associated with re-
circulation and migration on both the transcriptional (Figs. 2d, 4b)
and protein (Supplementary Information, Fig. S4d, e) level support
the possibility that blood ILC2 might be recruited to the lung, as
previously suggested in the mouse35,36 and in a human lung
allergen-provocation study.37 We therefore hypothesized that
exposure of blood ILC2 to an inflammatory type 2-deviating
environment could induce the lung ILC2 phenotype. To address this
possibility, we sorted and exposed blood ILC2 to the prototypical
ILC2-activating cocktail of alarmins (IL-2, IL-25, IL-33 and TSLP) and
assessed phenotypical changes (Supplementary Information,
Fig. S5). Indeed, alarmin exposure increased the expression of IL-
1RL1 and IL-17RB surface proteins on blood-derived ILC2 (Fig. 5a),
phenocopying lung ILC2. In parallel, the expression of CRTH2 was
downregulated, which we previously showed can be promoted by
alarmin-mediated endogenous production of the CRTH2 ligand
PGD2.
38 This finding raised the possibility that in the lung, alarmin-
activated ILC2 might not express CRTH2. Indeed, utilizing our
indexed flow cytometry data, evaluation of the composition of the
cluster annotated as lung ILC2 (Fig. 1d; Supplementary Information,
Fig. S3a) revealed a relatively high presence (35%) of CRTH2− ILCs
(ILC1 and ILC3 by FACS phenotype) among the lung ILC2 which was
not seen for blood or tonsil ILC2 where the majority of cells
expressed CRTH2 protein (Fig. 1d; Supplementary Information,
Fig. S3a). Evaluation of the transcriptional profile of CRTH2– vs
CRTH2+ cells showed that ILC2-related genes were present in
CRTH2– ILC2, and at higher levels and frequencies as compared to
lung ILC1 and ILC3 (Fig. 5b, c).
In summary, we reveal tissue-specific transcriptional differences
between ILC2 in blood, tonsil and lung particularly related to
migration, tissue-residency and sensing of the tissue microenvir-
onment. Exposure of blood ILC2 to an inflammatory type-2
environment lead to development of a lung-like phenotype
including downregulation of CRTH2. Thus, our transcriptional data
highlight heterogeneity among lung ILC2, specifically identifying
CRTH2− ILC2 with transcriptional similarities to bona fide CRTH2+
ILC2, including expression of the ILC2 effector molecule IL13.
Gene modules reveal subset- and tissue-specific profiles of ILC1-
like cells
Module 32 contained transcripts which were uniquely expressed
by putative ILC1 and EOMES+ ILC1 in blood and tonsil (Fig. 6a, b).
In line with previous reports,12,39 the module consisted of T cell-
related genes including CD3D, CD3E, CD3G, CD4, CD5, CD6 and
CD27. LEF1, a TF transcript described in tonsil ILC1,12 was also
expressed by blood ILC1. Notably, the transcripts in this module
were expressed by few lung ILC1 suggesting that blood and tonsil
ILC1 have more pronounced T cell features than lung ILC1
(Fig. 6b). Furthermore, indicating that blood and tonsil ILC1, and in
particular EOMES+ ILC1, are more related to NK cells than lung
ILC1, two additional transcriptional modules (Fig. 6b) revealed
transcripts expressed in NK cells as well as in ILC1 and EOMES+
ILC1 in blood and tonsil, and to a lesser extent by ILC1 in lung
(Fig. 6b).
Widespread predicted TCR V(D)J-rearrangement in blood ILC1-like
cells
Since putative ILC1 and EOMES+ ILC1 in blood and tonsil showed
characteristics of T cells, we performed a direct comparison
between blood ILCs and CD4+ T cells sorted in parallel from the
same peripheral blood donors (Supplementary Information,
Figs. S1 and S6). To understand the T cell identity of ILC1, we
analyzed TCR V(D)J-rearrangement using MiXCR.40 In contrast to
the T cell population, which as expected predominantly consisted
of cells with rearranged TCR-α and -β chains, ILC2 and nILCs
showed minimal V(D)J rearrangement across any of the TCR
chains (Fig. 7a; Supplementary Information, Fig. S7a). This stood in
sharp contrast to putative blood ILC1 and EOMES+ ILC1, where
most of the cells had undergone TCR rearrangement (Fig. 7a;
Supplementary Information, Fig. S7a), despite lacking surface
expression of TCR α/β, γ/δ or CD3 (Supplementary Information,
Fig. S1a). While EOMES+ ILC1 mostly had predicted rearrangement
in α- and/or β-TCR chains, blood ILC1 showed predicted
rearrangement in all four TCR chains (Fig. 7a; Supplementary
Information, Fig. S7a). UMAP clustering revealed that blood ILC1
with α- and/or β-TCR rearrangement chains clustered with CD4+
T cells (AB_T_ILC1) (Fig. 7b–d; Supplementary Information, Fig. S7b,
c). DE analysis showed that while the majority of ILC1 expressed
transcripts of α- and/or β-TCR constant regions (TRA-C and TRB-C),
expression of CD4 as well as variable fragments of α- and/or β-TCR
genes (TRA-V and TRB-V) was more pronounced in ILC1 with α-
and/or β-TCR rearrangement (Fig. 7e; Supplementary Information,
Fig. S7d, e). ILC1 with rearrangement in predominantly δ-, but also
γ-TCR chains formed a distinct cluster (GD_ILC1) (Fig. 7c, d;
Supplementary Information, Fig. S7b) and concordantly expressed
fragments of γ- and/or δ-TCR variable chains (TRG-V and TRD-V) as
well as IKZF2 (Fig. 7e; Supplementary Information, Fig. S7d, e). In
contrast, EOMES+ ILC1, of which most had predicted rearrange-
ments in α/β chains, clustered with T cells in close proximity to
CXCR3+ Th1 cells41 (Fig. 7b–d; Supplementary Information,
Fig. S7c). DE analysis unveiled that EOMES+ ILC1 with predicted
rearrangement in α/β chains showed high expression of α- and/or
β-TCR constant and variable regions, as well as CD8A (Fig. 7e;
Fig. 3 Tissue- and subset-specific profile of ILC3. a UMAP visualization of annotated ILC3 and nILC clusters (C_, colon; L_, lung; B_, blood; T_,
tonsil; nILC, naïve ILC). Clusters are color coded based on annotated clusters (Fig. 1e). b Modules highly correlated with tissues and ILC3. The
figure shows a selection of genes per module, and their levels of expression within annotated clusters (Fig. 1e). c Expression of LTB4R on colon
ILC3 (top plot) and summary bar plot showing expression of LTB4R on colon ILC3, tonsil ILC3 and blood nILCs (bottom plot). Data in c (top) is
from one representative blood, tonsil and gut sample. Data are from six independent experiments with one tissue donor each (blood= 6,
tonsil= 8 and colon= 6). d UMAP visualization of unbiased graph-based clustering analysis of ILC3. Clusters are color coded based on
unbiased graph-based clustering analysis of all cells (Fig. 1d). e Trajectory analysis of nILCs and colon ILC3 displaying a selection of DE genes
for each colon ILC3 cluster (C_ILC3a–d). f Trajectory analysis of nILCs and lung ILC1, ILC2 and ILC3 displaying a selection of DE genes for each
lung ILC3 cluster (L_ILC3a–b). g UMAP visualization of NCR2 expression. Colored cells (shades of blue) indicate expression of NCR2 transcripts.
h UMAP visualization of IL22 expression. Colored cells (shades of blue) indicate expression of IL22 transcripts. Data in a, b, d–h is from ten
independent experiments with one tissue donor each (blood= 3, lung= 4 and colon= 3) integrated with data from.12
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Supplementary Information, Fig. S7d, e). Hence, EOMES+ ILC1 are
transcriptionally closely related to Th1 and cytotoxic T cells. Finally,
we evaluated the clonality of ILCs vs T cells. As expected from
healthy donor blood, most cells represented unique clones (Fig. 7f;
Supplementary Information, Fig. S7f). Among ILC1 and EOMES+
ILC1 with α/β rearrangement, there were six clones represented by
two or more cells (Fig. 7f; Supplementary Information, Fig. S7f).
Two of these clones were shared with T cells (Supplementary
Information, Fig. S7g).
In summary, in contrast to ILC2 and nILCs, the majority of blood
ILC1 and EOMES+ ILC1 are strikingly similar to CD4+ or CD8+ TCR
α/β+ T cells, respectively, in terms of expression profile, TCR
rearrangement and clonality. In contrast, blood ILC1 with
preferential δ-TCR rearrangement constitute a subset distinct
from T cells. Our conclusions were further strengthened when
comparing the transcriptional profiles of ILCs to blood CD3+
T cells and CD56+ NK cells in a publically available scRNA-seq data
set (Supplementary Information, Fig. S8), showing minimal
similarity between blood ILC1 with preferential δ-TCR rearrange-
ment and any of the T cell subsets (Supplementary Information,
Fig. S8e, f).
DISCUSSION
Previous reports have described tissue-specific transcriptional
imprinting of ILCs across multiple organs. However, these findings
originated from pre-defined ILC subsets sorted in bulk from mice2
or humans,3 neglecting heterogeneity in the sorted populations.
Here we used full-length scRNA-seq on individually sorted ILCs
allowing for integrated analysis of FACS phenotype and tran-
scriptome on the single-cell level. Additionally, we took a holistic
and unbiased approach to analyzing the scRNA-seq data by
complementing DE analysis with correlation analysis to identify
gene modules, thereby going beyond only describing markers
specific to each cell type. Through our approach, we have been
able to make a number of novel observations, accompanied by a
set of experimental functional studies, which advance our
understanding of human ILC biology and serve as a resource to
the immunology community.
We identified two distinct ILC clusters that lacked markers of
mature ILCs. In the blood, these cells expressed CD117, identifying
them as the previously described circulating progenitors of all
lineages of mature ILCs, including NK cells.4,17 The other cluster
consisted of predominantly CD117+ ILC from colon and lung. In
sharp contrast to circulating nILCs, these cells showed a
transcriptome compatible with tissue-residency, possibly repre-
senting a resident precursor to mature ILCs in these tissues. nILCs
are identified as ILC3 by flow cytometry,3 calling for a better cell
surface definition of these cells. Future studies should be aimed at
targeted sorting and enrichment of these cells based on e.g.,
expression of CD117 and lack of markers associated with mature
ILC subsets and activation such as CRTH2, HLA-DR and NKp44. This
might reveal nILC subsets polarized to specific fates in certain
tissues. Our in-depth unbiased transcriptional profiling of circulat-
ing and resident nILCs provide a road-map for such differentiation
studies of these cells and their role in disease conditions.
Parabiosis experiments in mice have suggested that ILCs in
mucosal and adipose tissues are largely tissue resident42 while
other reports have unveiled a recirculating behavior of colon ILC2
during N. brasiliensis infection.36 We identified gene modules
particularly enriched in naïve and mature ILCs in the colon and
lung including CD69 and transcripts encoding TFs (NR4A1-3, STAT3,
RORA and RARA) as well as transcripts involved in Notch-, Fos/Jun-
and NFκB signaling, many of which have previously been detected
in CD69+ T cells and NK cells in humans and mice.13,22 In sharp
contrast to colon and lung, naïve and mature blood ILCs showed
features of CD62L- and S1PR1-mediated recirculation, similar to
that described in mice.36 In the tonsil, we detected signs of both
recirculation and tissue-residency. These data align well with a
recent report on human ILC3 sorted in bulk from tonsils, spleen
Fig. 4 Tissue- and subset-specific profile of ILC2. a UMAP visualization of annotated ILC2 clusters (L_, lung; B_, blood; T_, tonsil). Clusters are
color coded based on annotated clusters (Fig. 1e). b Modules highly correlated with ILC2 or tissue. The figure shows a selection of genes per
module, and their level of expression within annotated clusters (Fig. 1e). Data are from ten independent experiments with one tissue donor
each (blood= 3, lung= 4 and colon= 3) integrated with data from.12
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Fig. 5 Exposure of blood ILC2 to alarmins recapitulates the lung ILC2 phenotype. a Expression of IL-1RL1, IL-17RB and CRTH2 protein on
the surface of blood ILC2 treated with an alarmin cocktail (IL-2, IL-25, IL-33 and TSLP) for 48 h. FMO, fluorescence minus one. b UMAP
visualization of annotated ILC clusters in the lung. Clusters are color coded based on annotated clusters (Fig. 1e). c Violin plot visualization of
differentially expressed genes in cells annotated as ILC2 with a FACS phenotype of ILC1 (L_ILC2_ILC1) or ILC3 (L_ILC2_ILC3) vs cells ILC1 or
ILC3, respectively. Data are from seven independent experiments with a total of 13 blood donors (a) or from ten independent experiments
with one tissue donor each (blood= 3, lung= 4 and colon= 3) integrated with data from12 (b, c). Bars in b represent means ± SD. Mann
Whitney test was used in a; **P < 0.01; ***P < 0.001.
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and blood.4 Additionally, in mice, lymph nodes harbor both
migratory and tissue-resident ILCs, the former more common for
ILC1.20 Although the tissue-residency and migratory profiles of
mouse ILCs seem largely conserved in humans, we did detect
some unique features of human ILCs in this regard. Most strikingly,
human ILC2 uniquely expressed S1PR2, opening up for the
possibility of selectively targeting this receptor to influence ILC2
migration during type 2 inflammation.
The colonic mucosa is continuously exposed to environmental
and intrinsic factors derived from the microbiota, diet and
secretions in the digestive system. Indeed, we detected the
highest expression of ILC3-related genes in this tissue, and also
the highest degree of heterogeneity among ILC3. These ILC3
represented a spectrum of cells ranging from those with a more
resting and recirculating phenotype, possibly constituting cells
recently recruited from the circulation, to cells expressing genes
encoding effector molecules, activation markers and molecules
involved in metabolism. These data align well with a recent
scRNA-seq study of ILCs in the mouse colon,8 although the precise
transcripts defining ILC3 subsets in the mouse colon was different
to those we identified here. Notably, we did not identify ILC1-
biased ILC3, as those recently reported in the human inflamed
colon,11 which is likely due to the non-inflamed nature of the
intestinal tissue in our analysis. Furthermore, our data confirm
previous reports that in stark contrast to the mouse, the human
healthy colon lacks ILC2 as defined by surface protein
expression.16,43 Our data now further conclusively demonstrate
that the human colon is also largely devoid of ILCs with a
transcriptome reminiscent of ILC2. These results provide a
blueprint of the homeostatic situation of ILCs in the human colon,
aiding studies of the role for ILCs in colon immunopathology.
In the lung, we identified ILC2 with a transcriptome indicative of
activation, including expression of receptors of both IL-25 and IL-
33, reminiscent of natural ILC2 described in mice.44 The lung-
specific transcriptome of ILC2 could be a result of the constant
exposure of the lung to both extrinsic and intrinsic immune
stimuli. Indeed, we could recapitulate the lung phenotype of ILC2,
with high expression of receptors for IL-33 and IL-25, and low
expression of CRTH2, by exposing circulating ILC2 to tissue-
derived alarmins. This indicates that activated ILC2 might not
necessarily express CRTH2, which has previously been suggested
based on both mouse35 and human ex vivo37,45 and in vitro
data.38 Utilizing the power of our flow cytometry indexed scRNA-
seq data we were indeed able to identify such CRTH2– ILC2 in the
lung, expressing receptors for IL-33 and IL-25. In addition to
downregulation of CRTH2 on ILC2, CRTH2– ILC2 might also be
derived from ILC1 and/or ILC3 transdifferentiation. However, such
ILC2 plasticity from bona fide ILC1 or ILC3 has, to the best of our
knowledge, never been demonstrated in either mice or humans.
Nevertheless, our unbiased identification of CRTH2– ILC2 chal-
lenges our understanding of human ILC2 biology, and has
consequences for the identification of activated human ILC2 and
strategies to target these cells in type 2 inflammation in e.g.,
allergy and asthma. The failure of the CRTH2 antagonist
Fevipiprant in moderate-to-severe asthma46,47 may, at least in
part, be explained by our findings. The expression of the cell
surface receptor SLAMF1 could be helpful to distinguish CRTH2–
ILC2 from ILC1 and ILC3 in the lung.
The existence of ILC1 in different human tissues in homeostasis
and inflammation has been a topic of much debate.48–51 While
Tbet+ non-NK/T/B lymphocytes, fulfilling the definition of ILC1,
clearly accumulate in inflamed human intestinal tissues,16,52,53
Simoni et al. have suggested that in non-affected human tissues,
ILC1s are artifacts derived from contamination, by e.g., T cells. In
partial support of this, Roan et al. showed that a fraction (7%) of
blood ILC1 upregulate surface expression of TCRα/β following a 7-
day culture.39 While this shows that indeed blood ILC1 might
contain a small fraction of T cells that have downregulated their
surface TCRs, the majority of blood ILC1 are likely not T cells in
disguise despite expressing intracellular CD3 epsilon.39 In fact,
Fig. 6 Tissue and subset specific profile of ILC1. a UMAP visualization of annotated ILC1 and NK cell clusters. Clusters are color coded based
on annotated clusters (Fig. 1e). b Modules highly correlated with ILC1 and NK cells. The figure shows a selection of genes per module, and
their level of expression within annotated clusters (Fig. 1e).
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Fig. 7 Rearrangement of V(D)J T cell receptor genes in blood ILCs and T cells. a Predicted V(D)J-rearrangement of TRA, TRB, TRD and/or TRG
genes in annotated blood ILC clusters (B_ILC1, EOMES+ ILC1, B_ILC2 and B_nILC) and in donor matched CD4+ T cells (T). TRA_B,
rearrangement of TRA and TRB genes; TRG_D, rearrangement of TRG and TRD genes; TRA_B+ G_D, rearrangement of TRA and/or TCRB in
combination with TRD and/or TRG genes. b UMAP of blood ILCs and CD4+ T cells color-coded on the basis of annotation in Fig. 1e (B_ILC1,
EOMES+ ILC1, B_ILC2 and B_nILC) and CD4+ T cells (T). c UMAP displaying each subset in b separately and color-coding the cells on the basis
of predicted V(D)J-rearrangement of TRA and/or TRB (TRA_B), TRG and/or TRD (TRG_D) or TRA and/or TCRB in combination with TRD and/or TRG
genes (TRA_B+G_D). d Annotation of clusters on the basis of cell composition and predicted TCR V(D)J-rearrangement pattern. e Violin plot
representation of selected DE genes in AB_T_ILC1 cluster (top), GD_ILC1 (middle) and EOMES+ ILC1 (bottom). Within each cluster, data is
displayed separately for ILC1 and T cells, and also on the basis of TCR V(D)J-rearrangement pattern. f Number of cells with different clone
frequencies (based on third complementarity region 3 (CDR3)) per rearranged TCR chain for all ILC1 (top) and CD4+ T cells (bottom) in the
different clusters in d. Data are from three independent scRNA-seq experiments with one blood donor each. Total number of cells is 1036 (536
CD4+ T cells and 473 ILCs).
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CD3 epsilon overexpression in the absence of TCR expression in
mice has been suggested to block T cell development.54
Furthermore, cytoplasmic CD3 epsilon expression might indicate
that blood ILC1 are immature, as it is observed in fetal but not
adult NK cells.55 In further support of that, CD5+ ILCs, expressing
intracellular CD3 epsilon, have been suggested as precursors of
mature IFN-γ-producing ILC1.56 We identified a particularly
pronounced T-cell signature, including CD3E, encoding CD3
epsilon, in putative ILC1 and EOMES+ ILC1 in blood and tonsil.
We therefore analyzed TCR rearrangement to better understand
ILC1-T cell relationships. EOMES+ ILC1 and a subset of
ILC1 showed pronounced rearrangement in TCRα/β chains as
well as expression of CD4 and CD8A, respectively. Despite lacking
surface expression of TCRs and CD3, these ILCs might very well be
T cell contaminants, which was also supported by partial clonal
overlap between TCRα/β-rearranged T cells and ILC1. Clonal
overlap was however uncommon, and therefore it is also possible
that these ILCs are “failed T cells” with non-productive TCRα/β-
rearrangement, leading to a lack of surface TCR expression.
Notably, in ILCs, the expression of TCRα/β variable chains was
associated with TCRα/β rearrangement and could potentially be
used as a proxy for rearrangement in these cells.
We also identified a cluster of ILC1, which was transcriptionally
distinct from T cells, with rearrangement in predominantly TCR-δ
chains. Indeed, mouse NK cell precursors show V(D)J-recombina-
tion activity57 and up to a third of human blood NK cells display
rearrangement of δ-TCR chains.58 Hence, similar to intracellular
CD3 epsilon expression,55 δ-chain rearrangement in blood ILCs
might be a sign of immaturity and a history of recombination
enzyme activity.
In summary, our comparisons of ILCs and CD4+ T cells in human
blood unveiled clusters of putative ILC1 that show TCRα/β-
rearrangement and clonal overlap with T cells. The latter are likely
T cell contaminants with down-regulated surface TCRs while the
remainder could be “failed T cells”, with non-productive TCR
rearrangement. We also identified ILCs with TCR-δ rearrangement
reminiscent of immature ILCs, rather than differentiated Tbet+
ILC1. Our findings provide important first steps towards more
extensive, elaborate studies on rearrangement in subsets of T and
ILCs/NK cells across the innate and adaptive landscape and the
mechanisms, including development, underlying this unexpected
TCR rearrangement.
In conclusion, we used scRNA-seq to identify a plethora of ILC
subsets ranging from circulating and tissue-resident nILCs to
subsets of mature, activated and tissue-resident ILCs with altered
metabolism across four tissues. Deepened analysis unveiled
the presence of lung-specific CRTH2− ILC2, challenging our
understanding of ILC2-mediated diseases. Furthermore, TCR-V(D)
J rearrangement studies identified widespread predicted TCRα/β-
rearrangement and a distinct subset of putative immature ILCs
among the ILCs commonly referred to as ILC1 in peripheral blood.
Our findings constitute a roadmap for future studies




The Swedish ethical review authority approved all studies of
human tissues and all studies were performed according to the
Declaration of Helsinki. All regulations for work with human tissues
were complied with. All study subjects gave their informed written
consent prior to tissue collection.
Cell isolation from lung tissue
Lung tissue was obtained from four patients undergoing
lobectomy for lung cancer (age 57–76 year old, three females,
one male) at Karolinska University Hospital, Sweden. Non-affected
tissue was obtained distally from the tumor. None of the patients
had a diagnosis of asthma or chronic obstructive pulmonary
disease (COPD). All patients were ex-smokers. None of the patients
had received preoperative chemo- or radiotherapy. Lung cells
were isolated from human lung tissue by a sequential combina-
tion of washing, enzymatic digestion, mechanical disruption and
density centrifugation using Percoll gradient medium (WEMP
protocol), as recently published by us59 where all details of the
protocol can be found. Briefly, freshly resected lung tissue was
washed in PBS and cut into smaller pieces, then enzymatically
digested while stirring. The resulting digested product was cut
and mechanically disrupted by syringe plunging and filtering. The
filtered cell suspension was washed in PBS, resuspended in 30%
Percoll (one phase) and centrifuged. The cell pellet was
resuspended and red blood cells were lysed and washed with
PBS 2% fetal calf serum (FCS) and cells were counted. The cell
suspension was then stained with fluorescence-labeled antibodies
for FACS.
Cell isolation from whole blood
Peripheral blood mononuclear cells (PBMCs) were isolated from
whole venous blood from three healthy donors (age 29–32 year old,
two males, one female). 27mL of fresh blood was collected in EDTA
tubes and directly diluted 1:1 in PBS. PBMC were isolated via
lymphoprep (Axis Shield) and gradient centrifugation for 20min at
2000× rpm. Lymphocytes were then collected, washed and counted.
The cell suspension was then stained with fluorescence-labeled
antibodies for FACS.
Cell isolation from colon biopsies
Biopsies from the ascending colon were obtained from three tumor-
screening patients (age 57–71 year old, two males, one female) with
known genetic predisposition for colon cancer (hereditary non-
polyposis colorectal cancer (HPNCC) or Lynch Syndrome) but
without any polyps or tumors at the time of sampling. Colonosco-
pies were performed at Karolinska University Hospital or GHP
Stockholm Gastro Center, Sweden. Biopsy retrieval and cell isolation
was performed as previously described,16 where all the details of the
protocol can be found. Briefly, eight punch-biopsies per patients
were collected and transported in wash buffer, consisting of Hank’s
Balanced Salt Solution (HBSS) supplemented with antibiotics,
fungizone and HEPES. Samples were processed within 1 h of biopsy
retrieval. Wash buffer was removed and biopsies were enzymatically
digested while stirring. The filtered cell suspension was washed by
centrifugation and the total cell pellet was used for staining with
fluorescence-labeled antibodies for FACS.
Tonsil data
The previously published tonsil raw data used in this study can be
found at GEO: GSE70580; Sequence Read Archive: SRP060416.
Cell sorting
Isolated cells were incubated with live/dead cell marker (DCM;
Invitrogen) and surface protein antibodies (Supplementary
Information, Table S1) at 4 °C for 30 min, washed with PBS and
resuspended in Iscove’s modified Dulbecco’s medium IMDM
medium supplemented with 1% normal human serum (NHS;
Invitrogen) and Yssels supplement (made in house). Cells were
sorted into 384-well plates (Eppendorf) containing 2.3 μL of lysis
buffer per well. Lysis buffer (per well) consisted of 1.150 μL of 0.4%
Triton X-100 (Sigma), 0.4 μL dNTPs mix (25 mM) (Thermo Life
Tech), 0.05 μL Smart-dT30VN (100uM) (IDT), 0.05 μL RNAse inhibitor
(40 U/μL) (Takara), 0.0025 μL ERCC (1:40,000 dilution) (Ambion)
and 0.6475 μL of water (Thermo Life Tech). Cells were sorted on an
Aria FUSION sorter (BD Biosciences), with FACS Diva version
8 software and indexed data analysis enabled. Sorting of
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In vitro cultures
Sort-purified peripheral blood ILC2 (Supplementary Information,
Fig. S5) were cultured in IMDM (Fisher Scientific) supplemented
with 2% NHS and Yssels supplement in a 96 well plate. Cells were
left in culture for 48 h at 37 °C with IL-2 (10 U/mL) or IL-2 (10 U/
mL), IL-25 (R&D), IL-33 (PeproTech) plus TSLP (PeproTech) (at 50
ng/mL each). Following culture, the cells were washed and stained
with fluorescence-labeled antibodies for flow cytometry.
Flow cytometry
For flow cytometry analysis, cells were stained with DCM and
antibodies (Supplementary Information, Table S1) for 30 min at 4 °
C. Cells were washed in PBS supplemented with 2 mM EDTA and
2% FCS and fixed with 2% paraformaldehyde for 10min at room
temperature. Cells were acquired on an LSR Fortessa flow
cytometer (BD Biosciences) with FACSDiva software version 8.
Data were analyzed with FlowJo software version 9.9.6 (Tree Star).
Preparation of cDNA libraries and sequencing
Sorted cells were processed using the Smart-seq2 protocol with
minor changes.60 Sequencing was done to the average depth of
0.7 million reads per cell with 43 bp reads (single end) after
demultiplexing. Blood samples were additionally sequenced for V
(D)J analysis to and average depth of 0.84 million reads per cell
with 150 bp reads (paired end) after demultiplexing.
Read alignment and gene-expression estimation
The reads were aligned to the human genome (hg19–GRCh38)
and spike-in sequences (from the External RNA Controls Con-
sortium) using STAR v2.5.3a,61 and filtered for uniquely mapping
reads. Counts per gene were calculated for each transcript in
Ensembl release 92 using rpkmforgenes.62
Data filtering and normalization
Bioinformatics analyses were performed using R programming
language, using Seurat v3 package63 with modifications. Reads
were normalized to transcripts per million reads (TPMs) in order to
compensate for gene length in transcript count estimation. Values
were then multiplied by the read length (43 bp) and rounded to
the nearest integer. Cell libraries were considered of low quality
and filtered out if: (1) the percentages of mitochondrial and
ribosomal gene families were above 40% or 50%, respectively; (2)
the percentage of protein-coding genes was below 50%; (3) the
number of unique genes in a cell was below 200. Genes detected
in less than five cells were excluded from the analysis. Counts
were next log-normalized with scale factor of 1000 and Z-score
transformed for regression of confounding factors such as effects
related to mitochondrial, ribosomal, Y chromosome, cell cycle, sex
and proportion of non-coding RNA.
Dimensionality reduction and clustering
Normalized data were further processed for identification of
highly variable genes using the Scran method64 and linear data
compression using principal component analysis (PCA) from
which the top 50 principal components (PCs) explaining about
70% of the variance in the dataset were chosen for downstream
analysis. Non-linear dimensionality reduction was run on the top
50 PCs using UMAP15 and embedded into two final dimensions.
Graph construction was also run on the top 50 PCs using
approximate nearest neighbor (KNN)65 search with k= 10,
reflecting the minimum number of cells expected to be
considered a potentially rare cell cluster. Spurious connections
were filtered using shared nearest-neighbors (SNN) search using
Jacquard’s index of 1/15. Unsupervised graph clustering was run
using the Louvain method, in which the modularity resolution
parameter (res= 2.4) was optimized to match both known sample
metadata information as well as a coherent cluster distribution
across the UMAP embedding.
Differential expression and gene module identification using
WGCNA
Identification of marker genes associated to specific cell clusters
was done using differential expression via MAST.66 For standard
differential expression log2FC > 0.25 and false discovery rate
(FDR) < 0.01 was used.
For identification of the most relevant genes across cell clusters
to be later used for weighted gene correlation network analysis
(WGCNA),67 a permissive threshold with absolute log2FC > 0.1 and
P value < 0.1 was used. Briefly, the 4410 genes identified in this
manner were used for calculation of gene-to-gene Pearson
correlations. The adjacency matrix was directly used for creation
of the topological overlap matrix (TOM) using again Pearson as
correlation measure. Power transformation of adjacency values
were ignored since it would result in flattening all values to near 0,
as even strong single-cell correlations rarely reach close to 1 due
to the nature of data sparsity. No significant differences in the
results were found when using Pearson and Spearman correla-
tions, and therefore Pearson correlations were kept due to its
faster overall performance. Gene module identification was done
with agglomerative hierarchical clustering on the TOM using
Ward’s squared linkage (Ward.D2) with a fixed number of 100
modules. Gene counts belonging to the same module were
normalized between 0–1 individually and then averaged per cell
for calculation of each gene module expression pattern.
Modules were prioritized by fitting a general linear model (GLM)
using each gene module expression pattern as the effect and the
sample metadata as explaining variable. Each module and metadata
parameter was tested independently. The output of the GLM fit
results in the residual metric of “deviance” (devmodel) after fitting the
model and “null deviance” (devnull) when considering a NULL model.
The percent difference in these two deviances (Δdev) was used as a
measure of how much a particular metadata factor explains the
expression pattern of a gene module:
Δdev ¼ devnull  devmodel
devnull
This way, modules with higher Δdev were prioritized for further
exploration throughout the manuscript. Modules enriched for
ribosomal, mitochondrial and other known housekeeping families
were mentioned but not further analyzed.
Trajectory inference analysis
Trajectory inference analysis was performed using Slingshot v.1.2.025
on the Diffusion Map embedding (using five components), since the
UMAP embedding creates a distorted representation of the original
space. Lineages were defined by setting the naïve clusters (nILC) as
the root, and curves were projected onto the Diffusion Map
embedding for visualization.
TCR rearrangement analysis
For blood data with 150 bp PE sequencing, MiXCR40 was run on all
cells using the “analyze shotgun” command and default settings.
To avoid false positives MiXCR output was filtered for clones with
count > 5. If multiple predicted clones were found, only dominant
predicted clone from each chain (TRA, TRB, TRD or TRG) was
included in downstream analysis.
Analysis of human 10× genomics scRNA-seq PBMC data
Human PBMC data with 10× Genomics scRNA-seq, cell surface
protein detection with antibody-derived tags (ADT) and V(D)J assay
was downloaded from the 10× genomics website (https://
support.10xgenomics.com/single-cell-vdj/datasets/3.0.0/vdj_v1_hs_
pbmc2_5gex_protein). Dimensionality reduction and clustering was
performed with Seurat v3.1.3 with the whole dataset. T-cell and NK-
cell clusters were selected based on the protein expression, e.g.
CD3+ and CD56+CD3– clusters were selected for further analysis.
Article
13
Cell Research (2021) 0:1 – 15
Clustering and dimensionality reduction was performed again with
this subset, as shown in Supplementary Fig. 8a, b and cell types
annotated based on top DEGs using MAST (Supplementary
Information, Fig. S8c). At this stage, a contaminating cluster 8 that
is low in CD3 and CD56, but high in CD16 and CD19, was removed
as it likely represented doublets or cells that were wrongly clustered
in the first round.
To compare the 10× PBMC clusters to our blood SS2 data, we
looked at intersections of DEGs. All significant upregulated DEGs
(P < 0.01) for each cluster within the 10× data and SS2 data were
calculated separately. In the case of the AB_T_ILC1 cluster, cells
were separated into T-cells (AB_T) and ILCs (AB_ILC) and DEG
analysis was performed separately for those two groups. For each
comparison, phyper test P values were calculated for overlap
between the gene lists with all genes expressed in five cells in
both datasets as background.
For correlation between 10× PBMC and blood SS2 data, top 100
DEGs (or fewer if not 100 significant genes) from both datasets
were used to calculate mean expression for each cluster.
Spearman correlations between the clusters in each dataset were
then calculated for the mean expression.
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